DBV Technologies S.A. (DBVT) is producing an exclusive technology platform known as Viaskin, having a wide range of applications in immunotherapeutics and based on EPIT. It belongs to a new class of non-invasive candidate products. The safe transformation of food allergic patients’ care is the goal of the company.

DBVT stock price during the regular trading on March 14, 2022, declined 1.45% to be $1.36. Its price soared by 5.15% at the last check of the premarket session of March 15, 2022.

DBVT: Events and Happenings

On March 14, 2022, DBVT reported its CMO will present at the Oppenheimer’s 32nd Annual Healthcare Conference was held on March 17, 2022.

DBVT: Key Financials

DBVT released its full fiscal year 2021 financials on March 3, 2022, for the year ended December 31, 2021. Some significant features are shared here.

Revenue

Revenues in fiscal 2021 were $5.7 million against $11.2 million in fiscal 2020. The company observed an increase of $5.56 million in its revenue YoY.

EPS

FY 2021 net loss basic and diluted per share was $97.8 million or $1.78 compared to $159.5 million or $2.95 for the comparable year 2020. The company’s EPS nose-dived YoY. Also, its EPS remained in line with the expectations.

On February 22, 2022, DBVT updated on the participation of its management at the Annual Scientific Meeting of the American Academy of Allergy, Asthma, and Immunology on February 24-28. On February 14, 2022, DBVT announced the presentation of its CEO at the 11th Annual SVB Leerink Global Healthcare Conference on February 18. On January 21, 2022, DBVT issued its half-yearly statement of its liquidity agreement with ODDO BHF.

Conclusion

DBVT stock plunged deep in the last six months by 73%. Its current stock position is good as the company announced its Executive management’s participation at the Oppenheimer’s Healthcare Conference, hence its stock price surged in the premarket. For the first quarter of 2022, the company’s expectation of revenue is $1.28 million and -$0.40 EPS.